Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.